The DOI matches its Crossref record.
Schizophrenia: A New Approach
Abstract
Mr. Gladstone, with that candour which a great Statesman can afford, once said, “Government is a rough business, and the results are most unsatisfactory.” Unfortunately no great psychiatrist has described the present state of our knowledge and treatment of schizophrenia in an equally robust phrase; but surely, “rough business and unsatisfactory results” would not be an unfair summing up ? We have now known of this illness for nearly half a century, and yet our understanding of it is slight and our useful information scanty. This is not because we have been idle, but because our efforts have been poorly rewarded. Thousands of papers are written every decade; tens of thousands of observations are made; there is no lack of opportunity for studying patients when about one hospital bed in five in this country is occupied by a schizophrenic, yet we are still entirely ignorant of the cause of this disease. There are, it is true, numerous theories, but none is generally accepted. We have one form of treatment, deep insulin, which produces remission of symptoms in some cases and what seems to be a cure in others, but even the value of this treatment is hotly disputed. Because deep insulin is a purely empirical procedure the psychiatrist is always tempted to become preoccupied with details of technique so that he forgets, or at least becomes less aware of our fundamental ignorance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529
Stein, L., & Wise, C. D. (1971) · Science · doi:10.1126/science.171.3975.1032 · Cited by 477
Schizophrenia: Some Current Neurochemical Approaches
Rodnight, R. (1983) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1983.tb11809.x · Cited by 460
Enhancement of recovery from psychiatric illness by methylfolate
Godfrey, P. S. A., Toone, B. K., Bottiglien, T., Laundy, M., Reynolds, E. H., Carney, M. W. P., Flynn, T. G., & Chanarin, I. (1990) · The Lancet · doi:10.1016/0140-6736(90)91942-4 · Cited by 389
A REVIEW OF THE CLINICAL EFFECTS OF PSYCHOTOMIMETIC AGENTS
Osmond, H. (1957) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1957.tb40738.x · Cited by 365
Self-citationHistory of the Discovery and Clinical Introduction of Chlorpromazine
López-Muñoz, F., Alamo, C., cuenca, E., Shen, W., Clervoy, P., & Rubio, G. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230591002002 · Cited by 354
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293
Schizophrenia: A New Approach. II. Result of a Year's Research
Hoffer, A., Osmond, H., & Smythies, J. (1954) · Journal of Mental Science · doi:10.1192/bjp.100.418.29 · Cited by 298
Self-citationOxidative Damage and Schizophrenia: An Overview of the Evidence and Its Therapeutic Implications
Yao, J. K., Reddy, R. D., & van Kammen, D. P. (2001) · CNS Drugs · doi:10.2165/00023210-200115040-00004 · Cited by 280
Neuropharmacology of N,N-dimethyltryptamine
Carbonaro, T. M., & Gatch, M. B. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.016 · Cited by 268
Biochemical and toxicological properties of the oxidation products of catecholamines
Bindoli, A., Rigobello, M. P., & Deeble, D. J. (1992) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(92)90182-g · Cited by 264
Naloxone-induced reversal of schizophrenic hallucinations
Gunne, L. M., Lindstr�m, L., & Terenius, L. (1977) · Journal of Neural Transmission · doi:10.1007/bf01250276 · Cited by 262
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Barker, S. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00536 · Cited by 177
Barker, S. A., McIlhenny, E. H., & Strassman, R. (2012) · Drug Testing and Analysis · doi:10.1002/dta.422 · Cited by 142
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
Close, J. B., Hajien, E. C., Watts, R., Roseman, L., & Carhart-Harris, R. L. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2020.01.005 · Cited by 54
Dean, J. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00232 · Cited by 37
Metadata
- Authors
- Osmond, H., & Smythies, J.
- Venue
- Journal of Mental Science
- Publisher
- Royal College of Psychiatrists
- Published
- 1952-04
- Volume
- 98
- Issue
- 411
- Pages
- 309-315
- ISSN
- 0368-315X (ISSN-L)
- 2514-9946
- OpenAlex
- W2129374552
- Cited by
- 472
- References
- 0
- FWCI
- 14.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.